Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$262.40 USD

262.40
779,523

+4.27 (1.65%)

Updated May 3, 2024 04:00 PM ET

After-Market: $262.41 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

United Therapeutics (UTHR) Q1 Earnings Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is iShares US SmallCap Equity Fac (SMLF) a Strong ETF Right Now?

Smart Beta ETF report for SMLF

United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy United Therapeutics (UTHR) Ahead of Earnings?

United Therapeutics (UTHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?

Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

UTHR vs. ZTS: Which Stock Is the Better Value Option?

UTHR vs. ZTS: Which Stock Is the Better Value Option?

After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)

United Therapeutics (UTHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Why You Should Hold Molina Healthcare (MOH) in Your Portfolio

Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.

Should iShares S&P MidCap 400 Growth ETF (IJK) Be on Your Investing Radar?

Style Box ETF report for IJK

Encompass Health's (EHC) Plan Marks Entry in Rhode Island

Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.

Is iShares MSCI USA SmallCap Multifactor ETF (SMLF) a Strong ETF Right Now?

Smart Beta ETF report for SMLF

UTHR or ESALY: Which Is the Better Value Stock Right Now?

UTHR vs. ESALY: Which Stock Is the Better Value Option?

Centene (CNC) Wins Contract From DHCS to Serve Medi-Cal Members

Centene's (CNC) California subsidiary receives a contract from the DHCS to better address the health requirements of the state's Medi-Cal members.

Best Momentum Stock to Buy for January 4th

UTHR and AXON made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2023.